Cargando…

Resistance to Antimalarial Monotherapy Is Cyclic

Malaria is a prevalent parasitic disease that is estimated to kill between one and two million people—mostly children—every year. Here, we query PubMed for malaria drug resistance and plot the yearly citations of 14 common antimalarials. Remarkably, most antimalarial drugs display cyclic resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Weitzman, Rachel, Calfon-Peretz, Ortal, Saha, Trishna, Bloch, Naamah, Ben Zaken, Karin, Rosenfeld, Avi, Amitay, Moshe, Samson, Abraham O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836566/
https://www.ncbi.nlm.nih.gov/pubmed/35160232
http://dx.doi.org/10.3390/jcm11030781
_version_ 1784649711259484160
author Weitzman, Rachel
Calfon-Peretz, Ortal
Saha, Trishna
Bloch, Naamah
Ben Zaken, Karin
Rosenfeld, Avi
Amitay, Moshe
Samson, Abraham O.
author_facet Weitzman, Rachel
Calfon-Peretz, Ortal
Saha, Trishna
Bloch, Naamah
Ben Zaken, Karin
Rosenfeld, Avi
Amitay, Moshe
Samson, Abraham O.
author_sort Weitzman, Rachel
collection PubMed
description Malaria is a prevalent parasitic disease that is estimated to kill between one and two million people—mostly children—every year. Here, we query PubMed for malaria drug resistance and plot the yearly citations of 14 common antimalarials. Remarkably, most antimalarial drugs display cyclic resistance patterns, rising and falling over four decades. The antimalarial drugs that exhibit cyclic resistance are quinine, chloroquine, mefloquine, amodiaquine, artesunate, artemether, sulfadoxine, doxycycline, halofantrine, piperaquine, pyrimethamine, atovaquone, artemisinin, and dihydroartemisinin. Exceptionally, the resistance of the two latter drugs can also correlate with a linear rise. Our predicted antimalarial drug resistance is consistent with clinical data reported by the Worldwide Antimalarial Resistance Network (WWARN) and validates our methodology. Notably, the cyclical resistance suggests that most antimalarial drugs are sustainable in the end. Furthermore, cyclic resistance is clinically relevant and discourages routine monotherapy, in particular, while resistance is on the rise. Finally, cyclic resistance encourages the combination of antimalarial drugs at distinct phases of resistance.
format Online
Article
Text
id pubmed-8836566
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88365662022-02-12 Resistance to Antimalarial Monotherapy Is Cyclic Weitzman, Rachel Calfon-Peretz, Ortal Saha, Trishna Bloch, Naamah Ben Zaken, Karin Rosenfeld, Avi Amitay, Moshe Samson, Abraham O. J Clin Med Article Malaria is a prevalent parasitic disease that is estimated to kill between one and two million people—mostly children—every year. Here, we query PubMed for malaria drug resistance and plot the yearly citations of 14 common antimalarials. Remarkably, most antimalarial drugs display cyclic resistance patterns, rising and falling over four decades. The antimalarial drugs that exhibit cyclic resistance are quinine, chloroquine, mefloquine, amodiaquine, artesunate, artemether, sulfadoxine, doxycycline, halofantrine, piperaquine, pyrimethamine, atovaquone, artemisinin, and dihydroartemisinin. Exceptionally, the resistance of the two latter drugs can also correlate with a linear rise. Our predicted antimalarial drug resistance is consistent with clinical data reported by the Worldwide Antimalarial Resistance Network (WWARN) and validates our methodology. Notably, the cyclical resistance suggests that most antimalarial drugs are sustainable in the end. Furthermore, cyclic resistance is clinically relevant and discourages routine monotherapy, in particular, while resistance is on the rise. Finally, cyclic resistance encourages the combination of antimalarial drugs at distinct phases of resistance. MDPI 2022-01-31 /pmc/articles/PMC8836566/ /pubmed/35160232 http://dx.doi.org/10.3390/jcm11030781 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Weitzman, Rachel
Calfon-Peretz, Ortal
Saha, Trishna
Bloch, Naamah
Ben Zaken, Karin
Rosenfeld, Avi
Amitay, Moshe
Samson, Abraham O.
Resistance to Antimalarial Monotherapy Is Cyclic
title Resistance to Antimalarial Monotherapy Is Cyclic
title_full Resistance to Antimalarial Monotherapy Is Cyclic
title_fullStr Resistance to Antimalarial Monotherapy Is Cyclic
title_full_unstemmed Resistance to Antimalarial Monotherapy Is Cyclic
title_short Resistance to Antimalarial Monotherapy Is Cyclic
title_sort resistance to antimalarial monotherapy is cyclic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836566/
https://www.ncbi.nlm.nih.gov/pubmed/35160232
http://dx.doi.org/10.3390/jcm11030781
work_keys_str_mv AT weitzmanrachel resistancetoantimalarialmonotherapyiscyclic
AT calfonperetzortal resistancetoantimalarialmonotherapyiscyclic
AT sahatrishna resistancetoantimalarialmonotherapyiscyclic
AT blochnaamah resistancetoantimalarialmonotherapyiscyclic
AT benzakenkarin resistancetoantimalarialmonotherapyiscyclic
AT rosenfeldavi resistancetoantimalarialmonotherapyiscyclic
AT amitaymoshe resistancetoantimalarialmonotherapyiscyclic
AT samsonabrahamo resistancetoantimalarialmonotherapyiscyclic